C O Bingham 3rd
Overview
Explore the profile of C O Bingham 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garnero P, Aronstein W, Cohen S, Conaghan P, Cline G, Christiansen C, et al.
Osteoarthritis Cartilage
. 2007 Nov;
16(6):660-6.
PMID: 17993283
Objective: To investigate whether early changes in biochemical markers of bone (NTX-I) and cartilage (CTX-II [C-terminal crosslinking telopeptide of type II collagen]) degradation are associated with radiological progression in patients...
12.
Mor A, Bingham 3rd C, Kishimoto M, Izmirly P, Greenberg J, Reddy S, et al.
Ann Rheum Dis
. 2007 Aug;
67(4):462-5.
PMID: 17711866
Objectives: Reactivation of Mycobacterium tuberculosis (TB) is a significant problem with all available tumour necrosis factor (TNF) antagonists when used to treat rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and other...
13.
Bingham 3rd C, Sebba A, Rubin B, Ruoff G, Kremer J, Bird S, et al.
Rheumatology (Oxford)
. 2006 Aug;
46(3):496-507.
PMID: 16936327
Objective: To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies....
14.
Buckland-Wright J, Messent E, Bingham 3rd C, Ward R, Tonkin C
Rheumatology (Oxford)
. 2006 Jul;
46(2):257-64.
PMID: 16837470
Objectives: To determine whether risedronate (RIS) slows down trabecular bone loss in the medial compartment of the proximal tibia, a characteristic of patients with progressive knee osteoarthritis (OA). Methods: Initially,...
15.
Imperato A, Bingham 3rd C, Abramson S
Clin Exp Rheumatol
. 2004 Nov;
22(5 Suppl 35):S108-14.
PMID: 15552523
Targeted tumor necrosis factor-alpha antagonists, first approved by the FDA in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/ risk...
16.
Ho I, Arm J, Bingham 3rd C, Choi A, Austen K, Glimcher L
J Biol Chem
. 2001 Mar;
276(21):18321-6.
PMID: 11278438
We report a novel phospholipase A(2) (PLA(2)), group XII (GXII) PLA(2), distinct from other cysteine-rich groups with a catalytic histidine motif, by its 20-kDa size and distribution of the 14...
17.
Bingham 3rd C, Austen K
J Allergy Clin Immunol
. 2000 Feb;
105(2 Pt 2):S527-34.
PMID: 10669537
Many cells participate in the pathogenesis of asthmatic inflammation. The mast cell is localized at the interface of the internal and external environment within the lung where it may respond...
18.
Bingham 3rd C, Austen K
Proc Assoc Am Physicians
. 1999 Dec;
111(6):516-24.
PMID: 10591080
Phospholipase A2 (PLA2) enzymes cleave esterified fatty acids from membrane glycerophospholipids. The 20-carbon polyunsaturated fatty acid, arachidonic acid, is used as substrate by intermediate enzymes for the generation of eicosanoids,...
19.
Bingham 3rd C, Fijneman R, Friend D, Goddeau R, Rogers R, Austen K, et al.
J Biol Chem
. 1999 Oct;
274(44):31476-84.
PMID: 10531350
The subcellular location of the enzymes of eicosanoid biosynthesis is critical for their co-ordinate action in the generation of leukotrienes and prostaglandins. This activity is thought to occur predominantly at...
20.
Fujishima H, Sanchez Mejia R, Bingham 3rd C, Lam B, Sapirstein A, Bonventre J, et al.
Proc Natl Acad Sci U S A
. 1999 Apr;
96(9):4803-7.
PMID: 10220374
We have used mice in which the gene for cytosolic phospholipase A2 (cPLA2) has been disrupted to demonstrate the absolute requirement for cPLA2 in both the immediate and the delayed...